Evotec SE

NasdaqGS:EVO Voorraadrapport

Marktkapitalisatie: US$953.9m

Evotec Dividenden en inkoop

Dividend criteriumcontroles 0/6

Evotec heeft geen dividenduitkeringen gedaan.

Belangrijke informatie

n/a

Dividendrendement

0.2%

Terugkoop Rendement

Totaal aandeelhoudersrendement0.2%
Toekomstig dividendrendement0%
Dividendgroein/a
Volgende betaaldatum dividendn/a
Ex-dividenddatumn/a
Dividend per aandeeln/a
Uitbetalingsration/a

Recente updates van dividend en inkoop

Recent updates

Seeking Alpha • Jul 23

Evotec: Recovery Seems To Be Beginning

Summary Evotec remains a speculative 'Buy' with a €20/share price target, offering high long-term potential but requiring patience for upside realization. The company is refocusing on core strengths, expanding Evotec Biologics, leveraging AI, and executing cost-saving measures to improve profitability. Despite high leverage and recent revenue declines, strong partnerships, a robust pipeline, and operational improvements support my continued investment thesis. Risks are significant, but Evotec's growth prospects and current valuation justify maintaining my position for potential outsized returns over several years. Read the full article on Seeking Alpha
Seeking Alpha • Dec 29

Evotec: Some Recovery Has Come, But Much More Is Expected

Summary Evotec, a German drug discovery company, has shown strong top-line growth and significant partnerships, but struggles with financial performance and profitability, making it a speculative "Buy". Despite a 20% return since my last article, Evotec's stock remains volatile, with profitability expected around 2025-2026, driven by strong partnerships and strategic initiatives. The company has a solid liquidity position, low debt, and is on track with cost optimizations and strategic reviews, indicating potential for significant upside. I maintain a price target of €20/share ($11/share for the Nasdaq ticker), viewing Evotec as a speculative investment with a risk/reward-adjusted upside. Read the full article on Seeking Alpha
Seeking Alpha • Aug 30

Evotec: Weak Performance, But Long-Term Potential Is There

Summary Evotec's 28% decline is due to negative EBITDA despite solid top-line revenue growth, highlighting the need for patience in speculative investments. The company is restructuring, focusing on biologics and partnerships with BMY and others, aiming for profitability by 2025 or later. Valuation remains tricky; I cut my price target to $11/share due to delayed market recovery and sluggish revenue recognition. Evotec is a speculative "buy" with high potential but significant risks; I recommend holding and watching for now, not buying more. Read the full article on Seeking Alpha
Seeking Alpha • Apr 24

Evotec: Still A Speculative Buy After A Significant Decline

Summary Evotec SE's stock has declined over 30% in a single day, marking a 5-year decline of over 56%. The company's 2023A results met guidance, but the market expected more from the 2024E forecasts. The change in reporting structure and the stepping down of the CEO have also contributed to the decline in share price. I am still saying "Spec BUY", but with care. Read the full article on Seeking Alpha
Seeking Alpha • Oct 17

Amgen joins TIAP, Evotec at innovation hub for forming life science companies

Toronto Innovation Acceleration Partners (TIAP) and Evotec (NASDAQ:EVO) said the two companies expanded their translational BRIDGE partnership LAB150, to include Amgen (NASDAQ:AMGN) as a strategic partner. The expansion goes along with a combined investment of $14M to expedite LAB150 programs for forming new life science companies, Evotec said in a statement on Monday. TIAP and Evotec created LAB150 in 2017 to accelerate Toronto's academic research into market-ready products. Amgen will provide financial support for chosen LAB150 projects and mentorship from its drug discovery and development teams. In addition, Amgen Ventures will evaluate LAB150-derived companies for venture investment, Evotec noted. "Together with Evotec, we look forward to collaborating with Amgen to bring enhanced expertise and capital to LAB150 to enable life science company creation,” said TIAP President and CEO Parimal Nathwani.
Seeking Alpha • Sep 20

Evotec stock dips despite US DoD contract up to $49.9M to develop antibody for plague

Evotec (NASDAQ:EVO) (OTCPK:EVOTF) said the U.S. Department of Defense (DOD) awarded it a contract worth up to $49.9M for the rapid development of monoclonal antibody (mAb)-based drug product prototypes targeting plague. Under the agreement, Evotec's Seattle-based unit Just - Evotec Biologics will develop mAb-based drug product prototype(s) from sequence discovery or evaluation of existing mAbs to completion of phase 1 first-in-human (FIH) trials, the company said in a Sept. 20 press release. To enable rapid development, Just - Evotec will use its data-driven, automated biologics technology platform J.DESIGN and continuous manufacturing at its J.POD Redmond, Washington (U.S.) facility. Evotec will also provide pre-clinical and clinical capabilities for mAb prophylactic approvals. The contract was awarded by the Joint Project Lead for CBRND Enabling Biotechnologies within the DOD's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense in collaboration with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). EVO -5.24% to $9.41 premarket Sept. 20
Seeking Alpha • Aug 25

Evotec to acquire Central Glass Germany to bolster drug substance manufacturing

Evotec (NASDAQ:EVO) (OTCPK:EVOTF) is acquiring Central Glass Germany from Japanese chemical manufacturing company Central Glass Co. to expands its clinical and commercial manufacturing platform for small molecule therapeutics. Germany-based Evotec said in an Aug. 25 press release that the contract was signed on Aug. 24 at a purchase price of €1. Evotec added it intends to invest in the coming years to establish the facility as a European center of excellence for rare disease drug substance manufacturing. Evotec said Central Glass will now operate as Evotec Drug Substance (Germany) GmbH (Evotec DS). Central Glass is located on a pharmaceutical manufacturing campus in Halle/Westphalia and has a team of ~60 chemical manufacturing experts. The transaction is expected to close on Nov. 1, subject to conditions. Evotec noted that earnings accretion is expected to be achieved by 2023/24. EVO +1.11% to $11.87 premarket Aug. 25
Seeking Alpha • Aug 10

Evotec stock falls amid pact with Alpine for commercial process for potential lupus drug ALPN-303

Evotec (NASDAQ:EVO) said its Seattle-based unit Just - Evotec Biologics expanded a multi-year partnership with Alpine Immune Sciences (NASDAQ:ALPN) to develop a commercial process for ALPN-303. Evotec said ALPN-303 is being developed to treat systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases. The contract is a continuation of the companies first-in-human program initiated in 2020 in which Just - Evotec delivered drug substance materials for Alpine's ongoing phase 1 study and anticipated phase 2 studies of ALPN-303. Under the expanded contract, Just - Evotec Biologics will use its data-driven technology platform to develop a commercial manufacturing process for ALPN-303. The program includes upstream and downstream process, analytical method, and formulation development with a view to support commercial manufacturing of ALPN‑303. Commercial process development activities will be undertaken at Just - Evotec Biologics' J.POD biomanufacturing facility in Redmond, Washington. EVO -10.15% to $12.66 premarket Aug. 10
Seeking Alpha • Jul 06

Boehringer, Evotec, bioMérieux form joint venture Aurobac to combat antimicrobial resistance

Boehringer Ingelheim, Evotec (NASDAQ:EVO) (OTCPK:EVOTF) and bioMérieux formed a joint venture called Aurobac Therapeutics SAS to develop antimicrobials and diagnostics to fight Antimicrobial Resistance (AMR). Aurobac, which will develop a new precision medicine approach from diagnosis to cure, was funded with €40M in total with Boehringer Ingelheim investing €30M and Evotec and bioMérieux funding €5M each, according to the companies' July 6 press release. "Our role within the joint venture is to develop and commercialize diagnostic tests, including Companion Diagnostics, which deliver rapid, reliable and actionable results," said bioMérieux Chairman and CEO Alexandre Mérieux. Boehringer's participation in Aurobac is part of a wider pandemic preparedness initiative, which includes a €50M investment in AMR. Boehringer Ingelheim Venture Fund has committed to invest up to €12M in AMR infection companies.

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van EVO in het verleden stabiel is geweest.

Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van EVO zijn gestegen.

Dividendrendement versus markt

Evotec Dividendrendement versus markt
Hoe verhoudt EVO dividendrendement zich tot de markt?
SegmentDividendrendement
Bedrijf (EVO)n/a
Markt onderkant 25% (US)1.4%
Markt Top 25% (US)4.3%
Gemiddelde industrie (Life Sciences)0.8%
Analist prognose (EVO) (tot 3 jaar)0%

Opmerkelijk dividend: Het dividendrendement van EVO kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Hoog dividend: Het dividendrendement van EVO kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Winstuitkering aan aandeelhouders

Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio EVO te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat EVO geen uitbetalingen heeft gerapporteerd.

Ontdek bedrijven met een sterk dividend

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/17 17:13
Aandelenkoers aan het einde van de dag2026/05/15 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Evotec SE wordt gevolgd door 23 analisten. 10 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Christian EhmannBerenberg
Michael RyskinBofA Global Research
Peter VerdultCitigroup Inc